Sugi Predict

Sugi Predict / Compounds / SCHEMBL5372767

SCHEMBL5372767

SCHEMBL5372767

O=[N+]([O-])c1ccc2c(c1)c(-c1ccncc1)nn2C1CCCCO1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HPGD P15428 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ PKN1 Q16512 1/20 0.36
▸ PKN2 Q16513 1/20 0.36
▸ CYP4F2 P78329 2/20 0.36
▸ CYP4A11 Q02928 2/20 0.36
▸ MAPT P10636 4/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ PTGS2 P35354 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ AHR P35869 1/20 0.34
▸ SIRT2 Q8IXJ6 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ RET P07949 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CMKLR1 Q99788 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5383853 0.86 PTPN11 (0.47) L3MBTL1NPC1MAPTALDH1A1CNR2
SCHEMBL5386396 0.83 RET (0.40) CYP4F2CYP4A11ALDH1A1RETRXRA
SCHEMBL21198132 0.82 CYP1A2 (0.44) L3MBTL1HPGDCYP1A2NPC1MAPT
SCHEMBL28686145 0.81 SIRT2 (0.40) L3MBTL1HPGDCYP1A2NPC1MAPT
SCHEMBL5375050 0.81 CYP1A2 (0.39) L3MBTL1HPGDCYP1A2NPC1MAPT
SCHEMBL29672454 0.81 MAPT (0.40) L3MBTL1HPGDCYP1A2NPC1CYP4F2
SCHEMBL31482836 0.81 CYP1A2 (0.39) L3MBTL1HPGDCYP1A2NPC1MAPT
SCHEMBL29643977 0.81 SIRT2 (0.40) L3MBTL1HPGDCYP1A2NPC1MAPT
SCHEMBL16308649 0.81 MAPT (0.40) L3MBTL1HPGDCYP1A2NPC1CYP4F2
SCHEMBL27338781 0.81 MAPT (0.40) L3MBTL1HPGDCYP1A2NPC1CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220771-B2 Methods of using indazole derivatives as JNK inhibitors SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-22 — — US disclosed
US-7211594-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-01 — — US disclosed
US-7208513-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-04-24 — — US disclosed
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds SIGNAL PHARMACEUTICALS, LLC 2007-03-15 — — US disclosed
EP-1618093-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS Signal Pharmaceuticals LLC (US) 2006-01-25 — — EP disclosed
US-6897231-B2 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. (US) 2005-05-24 — — US disclosed
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SINGNAL PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 — — US disclosed
WO-2004094388-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2004-11-04 — — WO disclosed
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 — — US disclosed
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. 2004-04-22 — — US disclosed
EP-1313711-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2003-05-28 — — EP disclosed
WO-2002010137-A9 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARM INC (US) 2003-02-06 — — WO disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 — — US disclosed
WO-2002010137-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 L3MBTL1 2642/4885HPGD 1311/4885CYP1A2 2042/4885
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 L3MBTL1 3141/4885HPGD 1197/4885CYP1A2 994/4885
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds BCL9, MCL1, INMT L3MBTL1 1035/4885HPGD 1005/4885CYP1A2 331/4885
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 L3MBTL1 3245/4885HPGD 1073/4885CYP1A2 1038/4885
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 L3MBTL1 3141/4885HPGD 1197/4885CYP1A2 994/4885
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R L3MBTL1 3842/4885HPGD 1099/4885CYP1A2 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.